Brief: Radiopharm Theranostics Says U.S. FDA Granted Orphan Drug Designation To GA68-TRIVEHEXIN
09/05/2023 01:56
May 9 (Reuters) - Radiopharm Theranostics Ltd RAD.AX :
* U.S. FDA GRANTED ORPHAN DRUG DESIGNATION TO
GA68-TRIVEHEXIN (RAD
301)
Source text for Eikon: ID:nASX51d3gB
Further company coverage: RAD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%